These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25755849)

  • 21. Borderline resectable pancreatic cancer.
    Varadhachary GR; Tamm EP; Crane C; Evans DB; Wolff RA
    Curr Treat Options Gastroenterol; 2005 Oct; 8(5):377-84. PubMed ID: 16162303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
    White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
    Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer.
    Kharofa J; Mierzwa M; Olowokure O; Sussman J; Latif T; Gupta A; Xie C; Patel S; Esslinger H; Mcgill B; Wolf E; Ahmad SA
    Am J Clin Oncol; 2019 Mar; 42(3):247-252. PubMed ID: 30724781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.
    Cassinotto C; Dohan A; Zogopoulos G; Chiche L; Laurent C; Sa-Cunha A; Cuggia A; Reinhold C; Gallix B
    Eur J Radiol; 2017 Oct; 95():33-38. PubMed ID: 28987689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
    Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.
    Hayasaki A; Isaji S; Kishiwada M; Fujii T; Iizawa Y; Kato H; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Mizuno S; Usui M; Sakurai H
    Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29510561
    [No Abstract]   [Full Text] [Related]  

  • 30. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
    Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
    Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer.
    Blinn P; Shridhar R; Maramara T; Huston J; Meredith K
    J Gastrointest Oncol; 2020 Oct; 11(5):1078-1089. PubMed ID: 33209499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
    Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversies in the management of borderline resectable proximal pancreatic adenocarcinoma with vascular involvement.
    Tucker ON; Rela M
    HPB Surg; 2008; 2008():839503. PubMed ID: 19283083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer.
    Koay EJ; Katz MHG; Wang H; Wang X; Prakash L; Javle M; Shroff R; Fogelman D; Avila S; Zaid M; Elganainy D; Lee Y; Crane CH; Krishnan S; Das P; Fleming JB; Lee JE; Tamm EP; Bhosale P; Lee JH; Weston B; Maitra A; Wolff RA; Varadhachary GR
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma.
    Khattab A; Patruni S; Abel S; Hasan S; Ludmir EB; Finley G; Monga D; Wegner RE; Verma V
    J Gastrointest Oncol; 2019 Oct; 10(5):918-927. PubMed ID: 31602330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Portal-Mesenteric Vein Resection in Borderline Pancreatic Cancer; 33 Month-Survival in Patients with Good Performance Status.
    Tsiotos GG; Ballian N; Michelakos T; Milas F; Ziogou P; Papaioannou D; Salla C; Athanasiadis I; Razis E; Stavridi F; Psomas M
    J Pancreat Cancer; 2019; 5(1):43-50. PubMed ID: 31559380
    [No Abstract]   [Full Text] [Related]  

  • 39. Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland.
    Hyun JJ; Rose JB; Alseidi AA; Biehl TR; Helton S; Coy DL; Kozarek RA; Rocha FG
    J Surg Oncol; 2019 Aug; 120(2):262-269. PubMed ID: 31093997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.